Trial Profile

Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312), a Selective S1P1,5 Receptor Modulator, on Cardiac Repolarization: A Thorough QTc (TQT) Study

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 04 Nov 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Siponimod (Primary) ; Moxifloxacin
Indications Multiple sclerosis
Focus Adverse reactions
Sponsors Novartis Pharma A.G.

Most Recent Events

27 Oct 2015 Results published in the Clinical Therapeutics
29 Apr 2014 Results presented at the 66th Annual Meeting of the American Academy of Neurology.
28 Apr 2014 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com